doi: 10.1097/MOG.0000000000000423
Most of the other MCT1/4 inhibitors remain in preclinical stages and have not yet been tested in clinical trials, and further validation in clinical settings is required to establish their therapeutic potential [68, 69, 223]
Considering the slight difference in the rate of thyroid disorders (0.39 vs
Blood work can confirm whether you have a B12 deficiency or not
Quality standards in the grey market were long overdue for improvement, and enforcement actions, unfortunately, are often the catalyst
The 2023 trial enrolled a few hundred participants under selection criteria narrower than a marketed indication would carry, ran for under a year, and was powered for weight change rather than for the durability, cardiovascular, and rare-event questions that determine approval